Poseida Therapeutics, Inc. (NASDAQ:PSTX) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 3,100,000 shares, a drop of 17.8% from the March 31st total of 3,770,000 shares. Based on an average trading volume of 386,900 shares, the days-to-cover ratio is currently 8.0 days. Currently, 9.2% of the shares of the stock are sold short.
Poseida Therapeutics stock traded down $0.51 during trading hours on Tuesday, reaching $8.45. The company had a trading volume of 218,622 shares, compared to its average volume of 359,016. The company has a 50-day moving average price of $9.41 and a 200 day moving average price of $10.03. The firm has a market cap of $525.02 million and a price-to-earnings ratio of -1.23. Poseida Therapeutics has a 12-month low of $7.63 and a 12-month high of $17.62.
Poseida Therapeutics (NASDAQ:PSTX) last posted its earnings results on Thursday, March 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.11. Analysts anticipate that Poseida Therapeutics will post -3 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new position in shares of Poseida Therapeutics during the third quarter valued at approximately $30,000. Optimum Investment Advisors bought a new position in Poseida Therapeutics in the fourth quarter worth $33,000. Public Employees Retirement System of Ohio bought a new position in Poseida Therapeutics in the fourth quarter worth $35,000. JPMorgan Chase & Co. purchased a new position in Poseida Therapeutics during the third quarter valued at $45,000. Finally, Citigroup Inc. boosted its holdings in shares of Poseida Therapeutics by 582.9% during the 4th quarter. Citigroup Inc. now owns 4,405 shares of the company’s stock valued at $48,000 after buying an additional 3,760 shares in the last quarter. 41.09% of the stock is currently owned by hedge funds and other institutional investors.
Separately, Zacks Investment Research downgraded Poseida Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 17th.
About Poseida Therapeutics
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC.
Further Reading: What is a conference call?
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.